依帕司他片辅助治疗对糖尿病视网膜病变患者SOD、TAOC及TNF-α水平的影响(1)
摘要：目的 探究依帕司他片辅助治疗对糖尿病视网膜病变患者超氧化物歧化酶(SOD)、总抗氧化能力(TAOC)及肿瘤坏死因子-α(TNF-α)水平的影响。方法 选取2018年1月～2019年5月就诊于我院的糖尿病视网膜病变患者100例，按随机数字表法分为对照组和研究组，各50例。对照组采用前列地尔治疗，研究组在对照组基础上给予依帕司他片治疗。比较两组治疗效果、治疗前后SOD、TAOC及TNF-α水平。结果 研究组治疗总有效率(96.00%)高于对照组(84.00%)(P<0.05);治疗后，研究组SOD、TAOC水平高于对照组，TNF-α水平低于对照组(P<0.05)。结论 依帕司他片辅助治疗糖尿病视网膜病变的疗效优于单用前列地尔，且有助于改善患者SOD、TAOC及TNF-α水平。
关键词：糖尿病视网膜病变;依帕司他片;SOD;TAOC;TNF-α
中图分类号：R587.2;R774.1 文献标识码：A DOI：10.3969/j.issn.1006-1959.2020.05.030
文章编号：1006-1959(2020)05-0100-02
Abstract：Objective To explore the effects of adjuvant epalrestat on superoxide dismutase (SOD)， total antioxidant capacity (TAOC) and tumor necrosis factor-α (TNF-α) levels in patients with diabetic retinopathy. Methods A total of 100 patients with diabetic retinopathy who were admitted to our hospital from January 2018 to May 2019 were selected and according to the random number table method， divided into a control group and a study group， with 50 cases in each group. The control group was treated with alprostadil， and the research group was given epalrestat tablets on the basis of the control group. The treatment effects， SOD， TAOC and TNF-α levels were compared between the two groups. Results The total effective rate of treatment in the study group (96.00%) was higher than that in the control group (84.00%)(P<0.05). After treatment， the levels of SOD and TAOC in the study group were higher than those in the control group， and the levels of TNF-α were lower than those in the control group(P<0.05). Conclusion Epalrestat tablets are more effective in the treatment of diabetic retinopathy than alprostadil alone， and can help improve the levels of SOD， TAOC and TNF-α in patients.
Key words：Diabetic retinopathy;Epalrestat tablets;SOD;TAOC;TNF-α
糖尿病視网膜病变(diabetic retinopathy)为糖尿病严重并发症之一，早期无明显症状，随病变发展至视网膜黄斑区，会出现不同程度的视力下降、出血、斑点等，甚至失明，影响患者的身心健康[1]。可通过药物、激光疗法、玻璃体切割术等方式治疗，其中药物治疗因简单、安全、价格经济等优势被广泛用于临床。前列地尔可抑制血小板聚集、扩张血管，改善缺血区的供血情况，对早期糖尿病视网膜病变症状有改善作用[2]。依帕司他片是治疗糖尿病性神经病变药物，但有关前列地尔、依帕司他片联合治疗糖尿病视网膜病变以及关于两种药物对患者SOD、TNF-α、TAOC水平影响的研究较少。因此，本研究主要探究依帕司他片辅助治疗对糖尿病视网膜病变患者SOD、TNF-α、TAOC水平的影响，现报道如下。
1资料与方法
1.1一般资料 选取2018年1月～2019年5月就诊于天津市西青医院的100例糖尿病视网膜病变患者，本研究经我院医学伦理委员会批准[2018年审(124)号]，患者知情同意并签属知情同意书。将患者按随机数字表法分为对照组和观察组，各50例。对照组男29例，女21例;年龄43～79岁，平均年龄(61.50±2.35)岁;病程4～16年，平均病程(9.58±3.50)年。研究组男28例，女22例;年龄45～79岁，平均年龄(62.33±2.45)岁;病程5～16年，平均病程(9.45±3.47)年。两组性别、年龄、病程比较，差异无统计学意义(P>0.05)，研究有可比性。, http://www.100md.com(潘浩)
关键词：糖尿病视网膜病变;依帕司他片;SOD;TAOC;TNF-α
中图分类号：R587.2;R774.1 文献标识码：A DOI：10.3969/j.issn.1006-1959.2020.05.030
文章编号：1006-1959(2020)05-0100-02
Abstract：Objective To explore the effects of adjuvant epalrestat on superoxide dismutase (SOD)， total antioxidant capacity (TAOC) and tumor necrosis factor-α (TNF-α) levels in patients with diabetic retinopathy. Methods A total of 100 patients with diabetic retinopathy who were admitted to our hospital from January 2018 to May 2019 were selected and according to the random number table method， divided into a control group and a study group， with 50 cases in each group. The control group was treated with alprostadil， and the research group was given epalrestat tablets on the basis of the control group. The treatment effects， SOD， TAOC and TNF-α levels were compared between the two groups. Results The total effective rate of treatment in the study group (96.00%) was higher than that in the control group (84.00%)(P<0.05). After treatment， the levels of SOD and TAOC in the study group were higher than those in the control group， and the levels of TNF-α were lower than those in the control group(P<0.05). Conclusion Epalrestat tablets are more effective in the treatment of diabetic retinopathy than alprostadil alone， and can help improve the levels of SOD， TAOC and TNF-α in patients.
Key words：Diabetic retinopathy;Epalrestat tablets;SOD;TAOC;TNF-α
糖尿病視网膜病变(diabetic retinopathy)为糖尿病严重并发症之一，早期无明显症状，随病变发展至视网膜黄斑区，会出现不同程度的视力下降、出血、斑点等，甚至失明，影响患者的身心健康[1]。可通过药物、激光疗法、玻璃体切割术等方式治疗，其中药物治疗因简单、安全、价格经济等优势被广泛用于临床。前列地尔可抑制血小板聚集、扩张血管，改善缺血区的供血情况，对早期糖尿病视网膜病变症状有改善作用[2]。依帕司他片是治疗糖尿病性神经病变药物，但有关前列地尔、依帕司他片联合治疗糖尿病视网膜病变以及关于两种药物对患者SOD、TNF-α、TAOC水平影响的研究较少。因此，本研究主要探究依帕司他片辅助治疗对糖尿病视网膜病变患者SOD、TNF-α、TAOC水平的影响，现报道如下。
1资料与方法
1.1一般资料 选取2018年1月～2019年5月就诊于天津市西青医院的100例糖尿病视网膜病变患者，本研究经我院医学伦理委员会批准[2018年审(124)号]，患者知情同意并签属知情同意书。将患者按随机数字表法分为对照组和观察组，各50例。对照组男29例，女21例;年龄43～79岁，平均年龄(61.50±2.35)岁;病程4～16年，平均病程(9.58±3.50)年。研究组男28例，女22例;年龄45～79岁，平均年龄(62.33±2.45)岁;病程5～16年，平均病程(9.45±3.47)年。两组性别、年龄、病程比较，差异无统计学意义(P>0.05)，研究有可比性。, http://www.100md.com(潘浩)